P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning
This article was originally published in The Rose Sheet
With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.
You may also be interested in...
From Revlon’s latest celeb fragrances to OPI-inspired flip-flops, beauty launch news.
Soleo’s Marum GENtLE THERAPY Shampoo, marketed as an anti-dandruff and hair-growth treatment, is an unapproved new drug, according to FDA. The agency’s warning letter, citing “significant” CGMP violations, follows an August 2018 inspection of the firm’s Pyeongtaek-based facility.
Dr. Kurt Wolff’s study data for Alpecin Caffeine Shampoo is insufficient to support statements about hair-loss reduction, according to the Advertising Standards Authority’s March 28 ruling.